This study assesses the anti-arthritic effect of the affinin-enriched (spilanthol, main alkamide) hexane extract from the roots of Heliopsis longipes (A. Gray) S.F. Blake, Asteraceae, on a Freund adjuvant-induced arthritis model in rodents. The extract was orally administered at a dose of 2, 6.6, or 20 mg/kg; a significant edema-inhibitory activity in the acute and chronic phases was observed with a dose of 2 and 20 mg/kg, respectively. The extract showed higher anti-inflammatory and anti-arthritic effects than the reference drug phenylbutazone (80 mg/kg). Moreover, the extract prevented the occurrence of secondary lesions associated to this pharmacological model.
Introduction
Rheumatoid arthritis (RA) is an idiopathic auto-immune disease, characterized by symmetrical synovitis in large and small joints that may lead to progressive articular damage and disability (Mendoza-Vázquez et al., 2013) . Analgesic and anti-inflammatory drugs, including steroids, are used to suppress the symptoms. New therapies, like those targeting the tumor necrosis factor alpha (infliximab) or the anti-CD20 therapy (rituximab), which inhibit the underlying immune process, have been proposed. However, all these drugs have several undesired effects. Recent research aims to discover long-acting anti-inflammatory drugs with minimal side effects (Ekambaram et al., 2010) . A number of animal models are used to evaluate potentially useful compounds against RA, and the choice of a particular model depends on the immunological properties being observed in the model and their relation with the human disease. Among the available models is collagen-induced or adjuvant-induced (e.g., Freund's adjuvant) arthritis in rodents, spontaneous arthritis induced by TNF-␣ or genetic models, like the transgenic animal model. While no RA model can be considered ideal, Freund's adjuvant-induced rat arthritis shares several traits with human arthritis, and its sensitivity to evaluate anti-arthritic agents was the basis for its choice as the model to assess the activity of the Heliopsis longipes (A. Gray) S.F. Blake, Asteraceae, hexane extract (Ekambaram et al., 2010; Tanushree and Saikat, 2013) .
RA prevalence in developed countries is 0.5-2%, with an annual incidence of 12-1200 per 100,000 inhabitants. The female:male ratio is 2-3:1, and the peak age range of onset is 30-55 years old, but it could occur at any age. In Mexico, RA affects 1.6% of general population, being the main reason for consultation at the Rheumatology Service (Mendoza-Vázquez et al., 2013 ; Guía de Práctica Clínica, Diagnóstico y Tratamiento de Artritis Reumatoide del Adulto, México: Secretaría de Salud, 2009).
H. longipes is a perennial herb, endemic in a region comprising parts of Sierra de Alvarez and Sierra Gorda, near the triple border of San Luis Potosi, Guanajuato and Queretaro, in Central Mexico. The common names for this plant are chilcuague, pelitre, golden root, and Aztec root (Cilia-López et al., 2008) . The paralyzing and toxic action against flies and other insects of H. longipes root extracts was discovered as similar as that of pyrethrins during World War II (Acree et al., 1945) .
Fortunately, chilcuague did not become extinct after the exportation boom, even though its wild population was severely reduced. To date, land plots solely dedicated to the cultivation of this species, disseminated either by seed or by cutting, can be found between Guanajuato and Queretaro; the root is fully developed after 2-3 years (García-Chávez et al., 2004) . It is the most economically important species in its genus; its root is used in the region as a cooking condiment, and it is added to alcoholic beverages to improve taste. In traditional medicine, chilcuague root is used to treat respiratory diseases, as an anesthetic to treat tooth and muscular aches, to treat buccal lesions, and as an anti-parasitic (Cilia López, 2007) . Several alkamides have been isolated from H. longipes, but affinin, also known as spilanthol ((2E,6Z,8E)-N-isobutyl-2,6,8-decatrienamide), was identified as the main alkamide in the plant (Molina-Torres et al., 1996; García-Chávez et al., 2004; Hernández et al., 2009 ). The oily substance causes intense lip numbness and tingling within a few minutes after placed in the mouth, and it also stimulates salivation (Correa et al., 1971) . H. longipes is also reported to produce analgesia and anti-inflammation in human dental and oral pathologies (Colvard et al., 2006) . Additionally, it has been reported that H. longipes dichloromethane extract showed analgesic activity, as demonstrated in vitro by releasing of gammaaminobutyric acid (GABA) in mouse brain slices; the increase in GABA release in a region of cerebral cortex leads to sustained analgesia, favoring a descendent inhibition of nociceptive spinal neurons (Ríos et al., 2007) .
With regard to anti-inflammatory activity, Hernández et al. (2009) evaluated H. longipes ethanolic extract and purified affinin on mouse ear edema induced by either arachidonic acid (AA) or phorbol 12-myristate 13-acetate (PMA), demonstrating a significant anti-inflammatory effect. DE 50 values of 0.8 mg/ear and 1.2 mg/ear were obtained, respectively, in the AA-induced edema model; nimesulide (1 mg/ear) was used as reference drug. In the PMA-induced edema model, the ethanolic extract and affinin showed a dose-dependent anti-inflammatory effect with DE 50 values of 2 mg/ear and 1.3 mg/ear, respectively, using indometacin (3 mg/ear) as reference drug.
On the other hand, Cilia-López et al. (2010) evaluated the analgesic activity of H. longipes ethanolic extract and affinin and their effect on the central nervous system on a mouse model; both affinin (1 mg/kg) and H. longipes root ethanolic extract (10 mg/kg) showed an analgesic action similar to ketorolac (6 mg/kg), as assessed by pain induction with acetic acid and thermal stimulation (hot plate); also, H. longipes extract and affinin showed a stimulant effect on the central nervous system comparable to caffeine, as measured by the Irwin test. Cariño-Cortés et al. (2010) evaluated the cytotoxic potential of H. longipes ethanolic extract by recording the variability in the count of micronucleated polychromatic erythrocytes induced by the extract and the ratio of polychromatic erythrocytes with respect to normochromatic erythrocytes; no significant cytotoxic effect was observed. However, brain histopathological studies showed necrotic changes in the gray matter, described as polioencephalomalacia and neurophagy, at a dose of 1000 mg/kg of ethanolic extract. No damage or histopathological change was observed in other organs (liver, heart, kidney, spleen, and lung).
Among the recent studies on H. longipes is the assessment of ethanolic extract and affinin as potential anti-mutagenic and anticarcinogenic agents. The anti-mutagenic properties of affinin were evaluated by adding it to several mutagens, either with or without S9 metabolic activation, in Salmonella typhimurium (TA98, TA100, and TA102 strains) cultures. Affinin significantly decreased the point mutations induced by 2-aminoanthracene (2AA) (40%) and decreased the DNA oxidative damage induced by norfloxacin (NOR) (37-50%). Additionally, it showed antioxidant properties capable of reducing the rate of 2AA-and NOR-induced mutation in S. typhimurium TA98 and TA102, respectively, which could be relevant to treat some pain symptoms related to anti-radical activity (Arriga-Alba et al., 2013).
Materials and methods

Plant material
Heliopsis longipes (A. Gray). S.F. Blake, Asteraceae, roots were collected on February 16, 2014, 2:14:59 pm, within the boundaries of a land plot in Beltran community (N 21 • 16.427 , W 100 • 0.2672 ) at 1780 m above sea level, Xichu municipality, in Guanajuato, Mexico. After proper identification, five plant specimens were deposited in the Isidro Palacios herbarium (SLPM), at the Universidad Autónoma de San Luis (No. 048150).
Extraction
Dry, ground H. longipes roots (1285 g) were macerated for three consecutive times: First component extraction was performed with 2.5 l of hexane for 2 h; then, the recovered extract solution (1750 ml) was evaporated, yielding a dark yellow, viscous oil (26.386 g, labeled as Hl-A). A second maceration was performed on the same plant material after the first extraction, adding 1.250 l of hexane and left for 24 h; extract solution (1 l) was recovered, and after evaporation it yielded 12.29 g of viscous oil, labeled as Hl-B. A third and last maceration was performed as described above, using 1.5 l of hexane for 4 h, recovering an extract solution (900 ml) and yielding 3.469 g of viscous oil, labeled as Hl-C. Each maceration was monitored by thin-layer chromatography. The Hl-A sample yielded 26.386 g of affinin (1), with a 95% purity.
HPLC and NMR analysis
High performance liquid chromatography (HPLC) analysis of the Hl-A sample was performed in a Waters 1525 Binary HPLC pump equipment, controlled by Breeze software. A 15 cm × 4.6 mm, C18 Kromasil 100-5 column was used, coupled to a diode array detector (maximum absorbance was set to 230 nm). A water-acetonitrile gradient from 60:40 to 30:70 in 25 min was used for elution, at a flow rate of 1 ml/min (Fig. 1) .
Magnetic nuclear resonance (NMR) measurements for the Hl-A sample were acquired in an Agilent 600 MHz, DD2, Oneprobe equipment for 1 H y 13 C in CDCl 3 solution, using tetramethylsilane as internal standard (Tables 1 and 2 ). Chemical shift readings were compared with those reported in the literature (Correa et al., 1971) .
Pharmacological assay Animals
All experiments were performed in accordance with ethical standards for experimental pain research in animals (Zimmermann, 1983 ) and the Mexican Official Standard for animal care and handling (NOM-062-ZOO-1999) . The experimental protocol (CIBIUG-P01-2016) was approved and overseen by the Institutional Ethics Committee for Care and Use of Laboratory Animals of the Universidad de Guanajuato. Inbred Wistar rats (250-300 g) and Balb/c mice (20-25 g), obtained from the Natural and Exact Science Vivarium at Universidad de Guanajuato, were used. Animals were housed in groups of six, under controlled temperature (23 ± 2 • C) and humidity (55 ± 10%), with a 12-h light/darkness cycle, and were familiarized with the Fig. 1 . Chromatogram of the Hl-A sample affinin (1), injected at a concentration of 1 mg/ml and read at a wavelength of 230 nm. environment one week before the experiments. Animals were allowed food and water ad libitum. Immediately after the experiments, all animals were sacrificed in a CO 2 chamber.
Acute toxicity assays
The DL 50 value per os was determined as reported by Lorke (1983) . Mice were treated with Hl-A doses of 10, 100, or 1000 mg/kg. Animals were maintained under close observation over a 14-day period. The weight of the animals was monitored throughout the experiments, and the death or survival of the animals was registered.
Anti-inflammatory activity
Arthritis syndrome was induced by a plantar intradermic injection (through a 20-gauge needle) in the right hind paw of 0.05 ml of complete Freund's adjuvant (Sigma Aldrich). This method, reported by Newbould (1963) , has been widely used to detect potential antiinflammatory drugs with anti-arthritic activity. Among the several adjuvant types available, the most commonly used in experimental animals is Freund's adjuvant; two varieties of Freund's adjuvant are used: Incomplete Freund Adjuvant (IFA) and Complete Freund Adjuvant (CFA). IFA consists in a mixture of surfactant and mineral oil, usually Arlacel and Drakeol; CFA also contains killed mycobacteria, usually Mycobacterium bovis BCG at a concentration of 1 mg/ml or less (Rojas-Espinosa, 2006). Edema degree was evaluated by the volume displacement method, using a PAN LAB digital plethysmometer. Volume displacement was recorded 24 h before and 8, 24, 48, 72, and 96 h after CFA injection. To complete the assessment of activity on arthritis induction, volume variations in the hind paw were recorded up to 25 days after injection. Phenylbutazone (reference drug, Sigma Aldrich, 80 mg/kg) or the Hl-A sample (in a dose of 2, 6.6, or 20 mg/kg) were administered p.o. 24 h before CFA injection and daily for 14 days after. The severity and progression of secondary lesions in test animals were also compared.
The percentage of edema inhibition was calculated for all animals in each treatment group with respect to a vehicle-treated control group. Differences between control and treatment groups were analyzed by Tukey's test. A p-value lower than 0.05 was regarded as statistically significant.
Results
Acute toxicity assays
The DL 50 value p.o. for the Hl-A sample was 775 mg/kg.
Anti-inflammatory activity
Progression of Freund's adjuvant-induced arthritis in rats CFA injection in the right hind paw caused inflammation, which peaked within the first 8 h. Then, inflammation slowly decreased until day 6 post-injection, had a slight increase after day 7, and showed a sustained increase until the end of the experiment. At day 16 post-CFA-injection and until the end of the period of study, inflamed lesions (secondary lesions) in the left hind paw were detected, as well as deformed front paws and increasing thickness in ears and tail (Fig. 2) .
Dosing
Each tested concentration of the Hl-A sample and of phenylbutazone was administered daily for 15 days. The first dose was administered 1 day before CFA injection in the right hind paw pad (Newbould, 1963) . Frequent measurements in the hind paws with a plethysmometer showed that the treatment with phenylbutazone and with the tested Hl-A concentrations (2, 6.6, or 20 mg/kg) inhibited inflammation in the hind paw during the dosing period. As shown in Fig. 4 , prophylactic treatment with the reference drug (phenylbutazone, 80 mg/kg) significantly inhibited the inflammatory effect of CFA injection 8 h after the stimulus, during the acute inflammation phase. This was observed again 24 h after injection; additionally, administration p.o. of Hl-A at a dose of 2 mg/kg inhibited the progression of acute-phase edema by 42.3% (F 4,20 = 4.7) ( Table 3 (Table 4 and Fig. 4) . On the other hand, Hl-A administration at the same dose showed a higher inhibition percentage than phenylbutazone in all chronic-phase days. Secondary lesions did not occur during the treatment period at all Hl-A doses (Fig. 5) , and rats from Hl-A-treated groups showed a better joint mobility.
No significant difference was observed in corporal weight between phenylbutazone-treated nor Hl-A-treated rat groups at any dose with respect to the control, untreated group.
Discussion
A number of animal models have been proposed to evaluate anti-inflammatory activity, like the use of substances such as formalin of dextran, which cause acute inflammation when injected in rat hind paws. However, these models require administering high doses of anti-inflammatory drugs like phenylbutazone, often near toxic values, to significantly inhibit inflammation (Domenjoz, 1960) . Another method is the subcutaneous implant of cotton pellets, a model that is more sensitive to steroid anti-inflammatory drugs but is relatively insensitive to non-steroid anti-inflammatory drugs like phenylbutazone (Winder et al., 1962) . The method used in this study is based on a syndrome more similar to rheumatoid arthritis, which is capable of detecting anti-inflammatory activity in a wide range of drug types useful to treat rheumatoid arthritis in humans (Pearson et al., 1961; Pearson and Wood, 1963) . Phenylbutazone, previously used in other models, was a suitable reference drug to inhibit inflammation caused by CFA injection in rat hind paw; no weight-loss was observed as reported with other drugs (Newbould, 1963) . In our study, phenylbutazone inhibited CFA-induced inflammation by 46.5% 8 h after injection (Table 3) , a very similar result to that reported by Abad et al. (1996) , who recorded an inhibition rate of 40% 24 h after stimulus, increasing to over 70% at 72 h and decreasing again to 40% at 96 h, remaining constant until the day 15. In our study, the control drug was discontinued on the chronic phase, but inhibition rate remained in a range of 23-27%, indicating a long-term effect. On the other hand, an inhibition range of 27.2-36.8% was observed in the Hl-A-treated group (20 mg/kg), higher than that of the phenylbutazone-treated animals.
The process underlying the occurrence of secondary lesions in the model herein used is non-infectious, and it is suggested to be result of a generalized immune response to the components of tubercle bacilli, disseminated after local administration (Warsman and Sharp, 1960) . Neither phenylbutazone-treated nor Hl-A-treated rats at any dose (2, 6.6, or 20 mg/kg) showed secondary lesions, in contrast with control, untreated animals (Fig. 5) ; this indicates that treatments modify the immune response.
On the other hand, the highest extract dose (20 mg/kg) was set to much lower value than the DL 50 value herein reported (775 mg/kg, p.o.), which allows us to regard it as a low-toxicity substance (Lorke, 1983) . Extract accumulation due to a daily administration for 15 days failed to cause any toxicity sign in the period of study. Therefore, herein we provide information supporting the potential anti-inflammatory usefulness of H. longipes hexane extract (Hl-A), which has affinin as its main constituent as shown by HPLC and NMR analysis. The potential usefulness as anti-inflammatory agent of the extract at a low dose (2 mg/kg) was demonstrated in the acute-phase inflammation of the model, while its antiinflammatory and anti-arthritic activity at higher but secure doses (20 mg/kg) was demonstrated in the chronic-phase inflammation of the model, with no occurrence of secondary lesions.
Conclusions
The hexane extract of H. longipes, of which affinin is the main constituent, has potential usefulness as an anti-arthritic agent. This study contributes to provide information supporting the traditional use of this plant species. It is noteworthy that the available information about this species would suffice to create a monograph and suggest the production of a phytopharmaceutical, which would help encouraging a standardized, high-quality cultivation of this plant species and improve the economy of peasants in Sierra Gorda, Mexico.
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